Related papers: Within-host HIV models with periodic antiretrovira…
In this paper we consider the evolution of the HIV infection under a highly effective treatment based on a combination of RTI and/or PI drugs. This is usually modelled with a set of ODEs where the drug efficacy is a constant. In this paper…
We propose a population model for HIV-TB co-infection dynamics by considering treatments for HIV infection, active tuberculosis and co-infection. The HIV only and TB only models are analyzed separately, as well as full model. The basic…
A simple deterministic model is proposed to represent the basic aspects concerning the effects of different antiretroviral treatment schedules on HIV incidence and prevalence of affected populations. The model mimics current treatment…
We study within-host HIV dynamics using a three--component nonlinear ordinary differential equation model for healthy CD4$^{+}$ T cells, infected CD4$^{+}$ T cells, and free virus. In addition to the baseline model without treatment, we…
We construct a seven-component model of the in-host dynamics of the Human Immunodeficiency Virus Type-1 (i.e, HIV) that accounts for latent infection and the propensity of viral mutation. A dynamical analysis is conducted and a theorem is…
With the launch of second line anti-retroviral therapy for HIV infected individuals, there has been an increased expectation on surviving period of people with HIV. We consider previously well-known models in HIV epidemiology where the…
Humans, domestic animals, orchard crops, and ornamental plants are commonly treated with antibiotics in response to bacterial infection. By curing infectious individuals, antibiotic therapy might limit the spread of contagious disease among…
We propose a population model for TB-HIV/AIDS coinfection transmission dynamics, which considers antiretroviral therapy for HIV infection and treatments for latent and active tuberculosis. The HIV-only and TB-only sub-models are analyzed…
Combination Antiretroviral Therapy (cART) succeeds to control viral replication in most HIV infected patients. This is normally followed by a reconstitution of the CD4$^+$ T cells pool; however, this does not happen for a substantial…
The development of potent drugs for the control of viraemia in people living with HIV means that infected people may live a normal, healthy life and offers the prospect of eliminating HIV transmission in the short term and HIV infection in…
It is now evident that the commonly accepted strategy for treatment of HIV/AIDS by highly active antiretroviral therapy (HAART) will not lead to eradication of HIV in a reasonable time. This is straightforward from the typical exponential…
A central challenge in Human Immunodeficiency Virus (HIV) public health policy lies in determining whether to universally expand treatment access, despite the risk of sub-optimal adherence and consequent drug resistance, or to adopt a more…
In this paper, we examine a well-established model for HIV wild-type infection. The algorithm for steepest descent method for fixed final-time is stated and a modified method for free final-time is presented. The first type of cost…
In this paper, we construct a model to describe the transmission of HIV in a homogeneous host population. By considering the specific mechanism of HIV, we derive a model structured in three successive stages: (i) primary infection, (ii)…
We propose and investigate a delayed model that studies the relationship between HIV and the immune system during the natural course of infection and in the context of antiviral treatment regimes. Sufficient criteria for local asymptotic…
Recent clinical studies have shown that HIV disease pathogenesis can depend strongly on many factors at the time of transmission, including the strength of the initial viral load and the local availability of CD4+ T-cells. In this article,…
Broadly neutralizing antibodies are promising candidates for treatment and prevention of HIV-1 infections. Such antibodies can temporarily suppress viral load in infected individuals; however, the virus often rebounds by escape mutants that…
In this paper, we propose a mathematical model for HIV-1 infection with intracellular delay. The model examines a viral-therapy for controlling infections through recombining HIV-1 virus with a genetically modified virus. For this model,…
One way in which the human immunodeficiency virus (HIV-1) replicates within a host is by infecting activated CD4+ T-cells, which then produce additional copies of the virus. Even with the introduction of antiretroviral drug therapy, which…
We study minimal mean-field models of viral drug resistance development in which the efficacy of a therapy is described by a one-dimensional stochastic resetting process with mixed reflecting-absorbing boundary conditions. We derive…